Onderneming Birzeit Pharmaceuticals Company Palestine Exchange
Aandelen
Farmaceutische producten
slotkoers
Andere beurzen
|
||
- | - |
25/02 | Birzeit Pharmaceuticals Company rapporteert resultaten voor het volledige jaar dat eindigde op 31 december 2023 | CI |
09/01 | Wat zegt het Gotham City rapport over Grifols? | RE |
Vakgebied
Verkoop per activiteit
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Medicines
100,0
%
| 47 | 100,0 % | 43 | 100,0 % | -8,31% |
Verkoop per regio
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Palestine
100,0
%
| 47 | 100,0 % | 43 | 100,0 % | -8,31% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Talal Nasereddin
CEO | Chief Executive Officer | 74 | 01-04-84 |
Director of Finance/CFO | - | 15-11-84 | |
Chief Tech/Sci/R&D Officer | - | 01-02-97 | |
Chief Tech/Sci/R&D Officer | 71 | 03-04-77 | |
Chief Administrative Officer | 54 | 01-01-92 | |
Comptroller/Controller/Auditor | - | 09-09-98 | |
Human Resources Officer | - | 06-01-09 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | - | 01-01-21 | |
Chief Administrative Officer | 54 | 01-01-92 | |
Talal Nasereddin
CEO | Chief Executive Officer | 74 | 01-04-84 |
Director/Board Member | - | 30-04-84 | |
Director/Board Member | - | 30-07-90 | |
Director/Board Member | - | 28-05-92 | |
Director/Board Member | - | 18-04-11 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 38 764 898 | 28 654 287 ( 73,92 %) | 0 | 73,92 % |
Bedrijfsgegevens
Sector
Vaira. 1 jan. | Kapi. | |
---|---|---|
+21,28% | 43,92 mld. | |
+24,47% | 23,09 mld. | |
+19,22% | 15,35 mld. | |
+12,87% | 13,61 mld. | |
+44,67% | 12,02 mld. | |
-9,92% | 7 mld. | |
-0,05% | 6,79 mld. | |
-8,87% | 5,73 mld. | |
+13,07% | 5,6 mld. |